WO2006030985A1 - 過酸化脂質の測定方法 - Google Patents
過酸化脂質の測定方法 Download PDFInfo
- Publication number
- WO2006030985A1 WO2006030985A1 PCT/JP2005/017558 JP2005017558W WO2006030985A1 WO 2006030985 A1 WO2006030985 A1 WO 2006030985A1 JP 2005017558 W JP2005017558 W JP 2005017558W WO 2006030985 A1 WO2006030985 A1 WO 2006030985A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- hne
- lipid peroxide
- measurement
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/362—Menopause
Definitions
- the present invention relates to a method for measuring lipid peroxide.
- Lipids in ecology are caused by active oxygen generated in the body, for example
- lipid peroxide such as 4-hydroxy-2-nonenal (HNE), malondialdehyde (MDA), and thiobarbituric acid reactant (TABARS). It has recently been clarified that such lipid peroxidation (lipid peroxide) is involved in various diseases such as arteriosclerosis, diabetes, ischemic heart disease, hypertension, and dyslipidemia. Yes. For this reason, in order to grasp the state of lipid peroxidation in the living body and use the results for the severity of the above-mentioned various diseases, pathologic evaluation, determination of therapeutic drugs and dietary policies, and evaluation of effects, Methods are being considered.
- HNE 4-hydroxy-2-nonenal
- MDA malondialdehyde
- TABARS thiobarbituric acid reactant
- the TBA method using the reaction of lipid peroxides with thiobarbituric acid, or the measurement of oxidative stress that measures the amount of conjugated dithiophene-added hemoglobin in hemoglobin in erythrocytes as a marker of oxidative stress A method has been proposed.
- HNE 4-hydroxy-2-nonenal
- a method for measuring this HNE using high-speed liquid chromatography has been developed and applied to clinical tests.
- a specific antibody against HNE anti-HNE antibody
- an immunological measurement method using this for ELISA has been proposed (Patent Document 1).
- Patent Document 1 JP-A-8-168394 Disclosure of the invention
- the conventional TBA method for measuring lipid peroxides, the addition of glutathione by the amount of moglobin, the HNE measurement method by high-performance liquid chromatography, etc. make it difficult to perform extraction operations and reaction product measurement operations. There was a problem that the constant sensitivity was low and the measurement accuracy was not sufficient. In addition, in the process of measurement using various types of chromatography mass spectrometers, etc., it is necessary to perform separation by column in order to remove similar substances that interfere with competition and improve sensitivity. It cost. In addition, there was a problem that the cost was high, such as relatively expensive equipment and maintenance costs.
- Patent Document 1 solves the above problems and has the advantage of being able to measure a large number of specimens in a short time.
- the amount of antibody used that is, anti-HNE antibody
- HNE could not always be measured with high sensitivity and high accuracy. For this reason, it is required to measure HNE with high sensitivity and high accuracy.
- lipid peroxides ie, HNE
- HNE lipid peroxides
- the present invention should solve the problems of the conventional lipid peroxide measurement technology, and the representative lipid peroxide 4-hydroxy-2-nonenal (HNE) has high sensitivity, high accuracy, To provide a new lipid peroxide measurement method that can measure changes in blood HNE associated with menopause and stress, such as infectious animal models and women, in a short time and at a low cost. Is an issue.
- HNE 4-hydroxy-2-nonenal
- the present invention solves the above-mentioned problems. First, it binds to two anti-HNE antibodies that specifically bind 4-hydroxy-2-nonenal (HNE) and to this anti-HNE antibody. Sandwich-type time-resolved fluorescence using modified antibodies A method for measuring lipid peroxide by immunoassay comprising the following steps:
- ⁇ 1> a step of immobilizing anti-HNE antibody A as a first antibody on a carrier to form a first antibody-immobilized carrier;
- ⁇ 2> a step of contacting a sample to be measured with the first antibody-immobilized carrier;
- ⁇ 4> contacting the second antibody with a modified antibody modified with a binding substance as a third antibody that binds to the second antibody;
- the invention of the present application is characterized in that, secondly, the binding substance in the first invention is piotin and streptavidin, and third, the lanthanide in the first or second invention is It is characterized by being at least one of samarium, europium, terbium and dysprosium.
- FIG. 1 is a schematic view illustrating the steps of a method for measuring lipid peroxide according to the present invention.
- Figure 2 shows the method of measuring lipid peroxide according to the present invention in the case of using two types of anti-HNE antibodies (the first antibody and the second antibody) and the third antibody, and using two types of anti-HNE antibodies. It is the figure which showed the result of the comparative evaluation with the case.
- FIG. 3 is a diagram showing the results of measurement and evaluation of each concentration of HNE by the lipid peroxide measurement method of the present invention.
- Fig. 4 shows the results of measurement and evaluation of each HNE concentration using the conventional lipid peroxide measurement method (competitive ELI SA).
- Figure 5 shows the results of measurement of blood HNE concentration in sepsis model animals (rats) by the lipid peroxide measurement method of the present invention (A), and the results of verification of the relationship between HNE concentration and MDPH oxidase (B)
- A lipid peroxide measurement method of the present invention
- B MDPH oxidase
- FIG. 6 is a graph showing the results of measuring the blood HNE concentration in a human subjected to psychological stress by the lipid peroxide measurement method of the present invention.
- Figure 7 shows the results of measuring the HNE concentration in human peripheral blood (A) and the relationship between HNE concentration and NADPH oxidase as an in vU ro experiment using the lipid peroxide measurement method of the present invention ( FIG. BEST MODE FOR CARRYING OUT THE INVENTION
- the present invention relates to 4-hydroxy-2-nonenal, which can be said to be the most representative lipid peroxide in the living body (especially in blood) from its production amount, reactivity (for example, stable binding to protein), physiological action, etc. (HNE) is the measurement target.
- the present invention is a sandwich-type time-resolved fluorescence immunoassay (TR-FIA) using two types of anti-HNE antibodies that specifically bind to HNE, and further comprises one of the two types of anti-HNE antibodies.
- TR-FIA time-resolved fluorescence immunoassay
- This is a method for measuring lipid peroxide using a modified antibody that binds to an anti-HNE antibody. Specifically, the process will be described with reference to the example of FIG. 1. Through the following steps, the measurement of the peroxidized lipid of the present invention can be realized. Ie:
- an anti-HNE antibody A is immobilized as a first antibody on a carrier such as a test tube, a culture dish or a measurement plate, and the carrier is used as a first antibody-immobilized carrier.
- the anti-HNE antibody A as the first antibody is preferably a monoclonal antibody in order to enhance the specific binding reaction with HNE.
- a sample to be measured for example, blood
- a sample to be measured is applied to the first antibody-immobilized carrier by a known method from a living body such as human monkey, mouse, rat, hudge, horse, etc.
- the first antibody on the first antibody-immobilized carrier is bound to the HNE or the HNE-added substance contained in the sample to be measured by bringing the sample to be measured into contact with the sample to be collected, pretreated and adjusted for dilution.
- the origin of the sample to be measured is not limited to the natural sample derived from the living body.
- the second antibody further binds to HNE or an HNE-added substance contained in the sample to be measured.
- the HNE or HNE-added substance is sandwiched between the first antibody and the second antibody (sandwich).
- the second antibody may be a polyclonal antibody.
- the cleaning solution may contain Tween-20 (registered trademark), Triton-X (registered trademark), etc. as a surfactant, and skim milk Nyushi serum albumin (BSA), etc., as a blocking agent. You may make it contain.
- the second antibody is combined with a binding substance as the third antibody.
- the modified antibody modified with is contacted to bind the second antibody and the third antibody.
- the third antibody is subjected to the fourth step.
- the lanthanide modified with a binding substance corresponding to the binding substance of the modified antibody in is contacted with the third antibody and the lanthanide via the binding substance.
- the first step, the fifth step, the first antibody, the sample to be measured, the second antibody, the third antibody and the lanthanoid is formed, and the fluorescence specific to metal ions emitted strongly by the lanthanide of the complex is measured with a spectrophotometer, a fluorescence measuring instrument, a multi-label counter, etc.
- the present invention even if the titers of the antibodies used (anti-HNE antibody A, which is the first antibody, and anti-HNE antibody B, which is the second antibody) are low, a representative sample in the serum of the sample to be measured is used. Since lipid peroxide HNE or HNE adducts can be measured with high sensitivity, high accuracy, in a short time, and at low cost, it can be used in clinical applications. In other words, the present invention having such characteristics makes it possible to measure changes in blood HNE associated with animal models of infectious diseases and women's menopause / stress load, which were difficult with conventional HNE measurement methods. it can.
- the present invention relates to arteriosclerosis, diabetes, ischemic heart disease, hypertension, hyperlipidemia, etc., which are associated with lipid peroxidation (peroxide fat), pathological evaluation, therapeutic drugs and diet It can be used to determine the therapy policy and determine the effect.
- the measurement method of the present invention can be used for evaluation of inflammation, menopause, psychological stress, smoking, alcohol drinking, etc. for which confirmation of the involvement of oxidative stress and lipid peroxidation has not been obtained. What can be done is also considered.
- the binding substance in the present invention is piotin and streptavidin.
- Piotin and streptavidin are biobinding substances, and their binding is specific and strong, so they are easy to handle.
- the lanthanum node is at least one of samarium, sucrose, terbium and dysprosium. .
- the fluorescence of lanthanoids has the following advantages. In other words, 1> the fluorescence lifetime is very long.
- ordinary organic fluorescent compounds have a fluorescence lifetime of several nanoseconds, but lanthanide fluorescence, Pium and terbium have a fluorescence lifetime of several hundred microseconds or more. 2> Stokes shift is very large.
- these lanthanides are excited by absorbing ultraviolet light and emit visible light above 500 nm.
- the strongest light emission wavelengths are about 615 nm for Palladium, about 643 nm for Samarium, about 545 nm for Tepium, and about 574 nm for Dysprosium.
- the half-value width of the fluorescence emission peak is about 10-20 ⁇ , which is very sharp.
- the method for measuring lipid peroxide disclosed in the present application can eliminate various short-lived background fluorescence by using a lanthanide having such characteristics, and can realize more sensitive measurement. .
- the anti-antibodies in the method for measuring lipid peroxides of the present invention may be commercially available or may be prepared by various known antibody preparation methods.
- the antigen in this case, ⁇
- the antigen can be purified from the serum immunoglobulin fraction of sensitized rat, mouse, rabbit, hedge, goat, etc. using an antigen affinity column (polyclonal antibody).
- polyclonal antibody an antigen affinity column
- Producing antibodies using a cell fusion method in which antibody-producing cells and myeloma cell lines are fused to produce fused cells (monoclonal antibodies); (Monoclonal monoclonal antibody).
- Example 1 will be described below, and the method for measuring lipid peroxide of the present invention will be described in more detail. Of course, the invention is not limited by the following examples.
- Example 1 Evaluation of a method for measuring lipid peroxide
- the method for measuring lipid peroxide of the present invention is a sandwich-type time-resolved fluorescence measurement using two types of anti-antibody antibodies. So, as a lanthanoid Using Eu 3+ , Sandwich-type time-resolved fluorescence measurement using two types of anti-HNE antibodies (first antibody and second antibody), and Sandwich-type using a pyotinylated antibody against the second antibody as the third antibody The time-resolved fluorescence measurement was compared and evaluated.
- the first antibody is a monoclonal antibody (2.5 g / ml, 100 / l / wel)
- the second antibody is a polyclonal rabbit antibody (3.6 jg / ml 50 1)
- the three antibodies used were piotinated rabbit rabbit IgG (7.5 / tg / ml, 50 1), and Eu 3+ used streptavidin-conjugated Eu 3+ -BHHCT.
- the fluorescence emitted by Eu 3+ was measured at a wavelength of 615M.
- the reaction solid phase was H fluorescence plate rFuloronuncj for fluorescence measurement, and fluorescence measurement was performed using ArvoSX1420.
- the results show that when two types of anti-HNE antibodies and a third antibody are used (indicated by the circle in Fig. 2), only two types of anti-HNE antibodies can be used. It was confirmed that the minimum detection sensitivity is about 10 times higher than the case (the graph indicated by the depression angle in Fig. 2).
- the fluorescence intensity in HNE of 0.001 nmol / mK 0.001 nmol / mK 0. lnmol / ml K. lnmol / ml Iniaol / mK lOnmol / ml and 100 nmol / ml was measured by sandwich time-resolved fluorescence measurement. did.
- Eu 3+ was used for the run-off node.
- the fluorescence intensity increased depending on the concentration of HNE.
- the higher the HNE concentration the more Eu 3+ that emits fluorescence binds to HNE via the first antibody, the second antibody, and the third antibody.
- the results shown in FIG. 3 confirmed that fluorescence measurement was possible even when the concentration of HNE was 0.0001 nmol / ml (0. IM).
- the measurement sensitivity of blood HNE is 100 000 times higher than the measurement sensitivity (about 0.1 lmM) of the conventional HNE measurement method (for example, JP-A-8-168394). Was confirmed.
- Example 2 Measurement of blood HNE concentration in a sepsis model animal (in vivo)
- LPS lipopolysaccharide
- Apocynin is an inhibitor of NADPH oxidase activity, suggesting that NADPH oxidase is involved in HNE production.
- Example 3 Measurement of blood HNE concentration in baboons subjected to psychological stress
- the evening measurements were taken at rest (rest in Fig. 6), during the color word test (CW in Fig. 6), and at the end of the color word test (recovery in Fig. 6).
- M-Phase menstrual period
- F-Phase ovulation period
- Human peripheral blood was fractionated into mononuclear leukocytes and polymorphonuclear leukocytes by density gradient centrifugation, and washed twice with a phosphate buffer (PBS, pH 7.3). Each fraction was resuspended in plasma, and LPS (7.2 ig / mL; dissolved in plasma) was added to prepare a measurement sample. This measurement sample (mononuclear leukocyte-containing sample and polymorphonuclear leukocyte-containing sample) was incubated at 37 for 10 minutes, 20 minutes, 30 minutes, 60 minutes, and HNE was measured.
- PBS phosphate buffer
- HNE 4-hydroxy-2-nonenal
- the third antibody and lanthanide can be bound more reliably, and lipid peroxide can be measured with higher sensitivity.
- the time-resolved fluorescence measurement using the long-lived fluorescence of the lanthanoid removes the fluorescence contained in the biological material, lowers the measurement background, and more efficiently measures lipid peroxide. can do.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006535252A JPWO2006030985A1 (ja) | 2004-09-16 | 2005-09-16 | 過酸化脂質の測定方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004269186 | 2004-09-16 | ||
| JP2004-269186 | 2004-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006030985A1 true WO2006030985A1 (ja) | 2006-03-23 |
Family
ID=36060218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/017558 Ceased WO2006030985A1 (ja) | 2004-09-16 | 2005-09-16 | 過酸化脂質の測定方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2006030985A1 (ja) |
| WO (1) | WO2006030985A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011158798A1 (ja) * | 2010-06-14 | 2011-12-22 | 国立大学法人山口大学 | 乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット |
| CN103105496A (zh) * | 2012-09-20 | 2013-05-15 | 河南生生医疗器械有限公司 | 一种时间分辨荧光法综合检测食管癌试剂盒及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH055739A (ja) * | 1991-06-28 | 1993-01-14 | Nippon Telegr & Teleph Corp <Ntt> | レーザ磁気免疫測定用検体調製方法 |
| JPH08168394A (ja) * | 1994-12-16 | 1996-07-02 | Nikken Food Kk | 4−ヒドロキシ−2−ノネナール修飾蛋白質に対するモノクローナル抗体とその製造法及びこれを生産するハイブリッド細胞並びに4−ヒドロキシ−2−ノネナール定量用免疫測定キット |
| JPH10160735A (ja) * | 1996-01-19 | 1998-06-19 | Meiji Milk Prod Co Ltd | サンドイッチ測定法 |
| JP2001324506A (ja) * | 2000-05-16 | 2001-11-22 | Ikagaku:Kk | 血液中の変性リポ蛋白の検出方法および動脈硬化症の診断用キット |
| JP2004108914A (ja) * | 2002-09-18 | 2004-04-08 | Kudo Norio | コラーゲンの測定方法 |
-
2005
- 2005-09-16 JP JP2006535252A patent/JPWO2006030985A1/ja active Pending
- 2005-09-16 WO PCT/JP2005/017558 patent/WO2006030985A1/ja not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH055739A (ja) * | 1991-06-28 | 1993-01-14 | Nippon Telegr & Teleph Corp <Ntt> | レーザ磁気免疫測定用検体調製方法 |
| JPH08168394A (ja) * | 1994-12-16 | 1996-07-02 | Nikken Food Kk | 4−ヒドロキシ−2−ノネナール修飾蛋白質に対するモノクローナル抗体とその製造法及びこれを生産するハイブリッド細胞並びに4−ヒドロキシ−2−ノネナール定量用免疫測定キット |
| JPH10160735A (ja) * | 1996-01-19 | 1998-06-19 | Meiji Milk Prod Co Ltd | サンドイッチ測定法 |
| JP2001324506A (ja) * | 2000-05-16 | 2001-11-22 | Ikagaku:Kk | 血液中の変性リポ蛋白の検出方法および動脈硬化症の診断用キット |
| JP2004108914A (ja) * | 2002-09-18 | 2004-04-08 | Kudo Norio | コラーゲンの測定方法 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011158798A1 (ja) * | 2010-06-14 | 2011-12-22 | 国立大学法人山口大学 | 乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット |
| CN103105496A (zh) * | 2012-09-20 | 2013-05-15 | 河南生生医疗器械有限公司 | 一种时间分辨荧光法综合检测食管癌试剂盒及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2006030985A1 (ja) | 2008-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3517652B2 (ja) | 中枢神経系の損傷を検出するためのアッセイ | |
| JP2013513107A (ja) | 自己抗体抗原結合を阻害するためのペプチド試薬及び方法 | |
| CA3181751A1 (en) | Detection of antibodies to sars-cov-2 | |
| CN110573863B (zh) | 用于检测分析物的方法 | |
| CN117368483A (zh) | 一种基于均相光激化学发光免疫分析技术的肾损伤分子-1检测方法及试剂盒 | |
| EP0804736B1 (fr) | Procede de dosage ultrasensible de la troponine i cardiaque | |
| JPH10511776A (ja) | レセプター:遊離リガンド(リランド)複合体ならびにそれに基づくアッセイおよびキット | |
| JPWO2004027424A1 (ja) | 蛍光化抗体を用いた蛍光分析方法 | |
| CN111727372A (zh) | 用于监测对核苷逆转录酶抑制剂疗法的遵守的产品和方法 | |
| WO2003083486A1 (fr) | Procédé d'évaluation de la cardiotoxicité d'une substance thérapeutique chimique anticancéreuse du type anthracycline par détection de la protéine de liaison d'acides gras du coeur humain (h-fabp) et réactif associé | |
| CN108020673A (zh) | Aβ试剂盒、检测方法及应用 | |
| JP2002296278A (ja) | 医療用キット | |
| EP2252897A2 (fr) | Procede de detection directe de l'albumine modifiee de l'ischemie par utilisation d'un partenaire de liaison a un derive aldehyde issu de la peroxydation de lipides sous forme liee | |
| WO2006030985A1 (ja) | 過酸化脂質の測定方法 | |
| JP4438455B2 (ja) | 遊離ヒトイムノグロブリン軽鎖の測定法及びキット | |
| Hiroyuki et al. | An enzyme immunoassay system for measurement of serum insulin | |
| JP2004069672A (ja) | 酸化アポリポタンパク質ai及びそれを含有する酸化リポタンパク質の測定法及びキット | |
| CN111735809B (zh) | 阿司匹林代谢及血小板高反应性的化学发光检测方法及检测试剂盒 | |
| JPS61230058A (ja) | アルブミンの定量法 | |
| CN114527286A (zh) | 一种全血检测甲状旁腺素的试剂盒及其使用方法 | |
| WO2004027423A1 (ja) | コラーゲンの測定方法 | |
| EP1412471B1 (en) | Apparatus and method for determining the onset and presence of sepsis conditions | |
| JP4588053B2 (ja) | 酸化アポリポタンパク質ai及びそれを含有する酸化リポタンパク質の測定法及びキット | |
| WO2007007792A1 (ja) | 抗体の検出法及び検出キット | |
| KR920010224B1 (ko) | 응집반응 측정법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006535252 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |


